Cargando…
Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
Currently, there is a paucity of evidence to guide the management of antipsychotic therapy at the end of life for patients with schizophrenia. A 51-year-old female with a diagnosis of palliative squamous cell carcinoma of the tonsils was admitted to her local hospice for end-of-life care. She had a...
Autores principales: | Hindmarsh, Jonathan, Huggin, Amy, Belfonte, Anya, Lee, Mark, Pickard, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241334/ https://www.ncbi.nlm.nih.gov/pubmed/34223460 http://dx.doi.org/10.1089/pmr.2020.0039 |
Ejemplares similares
-
Subcutaneous Levetiracetam Application Sustains Therapeutic Drug Levels
por: Westphal, Sophia, et al.
Publicado: (2021) -
Quality Versus Quantity of Life: Beyond the Dichotomy
por: Dempsey, Ariel, et al.
Publicado: (2023) -
Advances in Cardiopulmonary Life-Support Change the Meaning of What It Means to be Resuscitated
por: Avant, Leslie C., et al.
Publicado: (2020) -
A Case Report of COVID-19 in New Orleans, Louisiana: Highlighting the Complexities of Prognostication in a Critically Ill Patient
por: Lerner, Zachary I., et al.
Publicado: (2020) -
A Case of Nerve Root Radiofrequency Thermocoagulation for Pain Due to Pleural Metastasis of Lung Cancer Leading to Improvement in the Patient's Quality of Life
por: Tsuzuki, Yumi, et al.
Publicado: (2023)